These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34184431)

  • 1. Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus.
    Hare GMT; Zhang Y; Chin K; Thai K; Jacobs E; Cazorla-Bak MP; Nghiem L; Wilson DF; Vinogradov SA; Connelly KA; Mazer CD; Evans RG; Gilbert RE
    Physiol Rep; 2021 Jun; 9(12):e14890. PubMed ID: 34184431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
    Takakura S; Takasu T
    Biol Pharm Bull; 2019; 42(10):1707-1712. PubMed ID: 31582658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
    Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
    Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
    Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats.
    Chen L; LaRocque LM; Efe O; Wang J; Sands JM; Klein JD
    Am J Med Sci; 2016 Nov; 352(5):517-523. PubMed ID: 27865300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
    Zhang Y; Thai K; Kepecs DM; Gilbert RE
    PLoS One; 2016; 11(1):e0144640. PubMed ID: 26741142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
    Rajasekeran H; Reich HN; Hladunewich MA; Cattran D; Lovshin JA; Lytvyn Y; Bjornstad P; Lai V; Tse J; Cham L; Majumder S; Bowskill BB; Kabir MG; Advani SL; Gibson IW; Sood MM; Advani A; Cherney DZI
    Am J Physiol Renal Physiol; 2018 Mar; 314(3):F412-F422. PubMed ID: 29141939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced
    Hodrea J; Balogh DB; Hosszu A; Lenart L; Besztercei B; Koszegi S; Sparding N; Genovese F; Wagner LJ; Szabo AJ; Fekete A
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F1017-F1029. PubMed ID: 32116017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
    Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
    J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.
    Wilcox CS
    Hypertension; 2020 Apr; 75(4):894-901. PubMed ID: 32114848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockout of Na
    Song P; Huang W; Onishi A; Patel R; Kim YC; van Ginkel C; Fu Y; Freeman B; Koepsell H; Thomson S; Liu R; Vallon V
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F207-F217. PubMed ID: 31091127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
    Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS
    Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
    Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
    BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glomerular hyperfiltration with hyperglycemia in the spontaneously diabetic Torii (SDT) fatty rat, an obese type 2 diabetic model.
    Sano R; Ishii Y; Yamanaka M; Yasui Y; Kemmochi Y; Kuroki F; Sugimoto M; Fukuda S; Sasase T; Miyajima K; Nakae D; Ohta T
    Physiol Res; 2021 Mar; 70(1):45-54. PubMed ID: 33453716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH
    Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
    Hallow KM; Boulton DW; Penland RC; Helmlinger G; Nieves EH; van Raalte DH; Heerspink HL; Greasley PJ
    J Pharmacol Exp Ther; 2020 Oct; 375(1):76-91. PubMed ID: 32764153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.